针对软骨的药物纳米载体用于骨关节炎治疗
Luca Morici1, Eric Allémann1, Carlos Rodríguez-Nogales1
1School of Pharmaceutical Sciences, University of Geneva, Rue Michel-Servet 1, 1206 Geneva, Switzerland; Institute of Pharmaceutical Sciences of Western Switzerland, Rue Michel-Servet 1, 1206 Geneva, Switzerland.
International journal of pharmaceutics
|October 18, 2024
概括
开发有效的骨关节炎治疗方法需要克服软骨透的挑战. 本综述探讨了使用带正电荷的生物材料用于增强骨关节炎治疗的软体向药物递送系统 (DDS).
科学领域:
- 生物材料科学 生物材料科学
- 药物运输 药物运输 药物运输
- 骨关节炎研究 骨关节炎研究
背景情况:
- 骨关节炎 (OA) 是一种普遍存在的全球关节疾病,由于软骨透性差,目前没有疾病修饰药物 (DMOADs).
- 针对细胞外基质 (ECM) 对于OA治疗至关重要,需要专门的药物递送系统 (DDS).
研究的目的:
- 审查健康和OA软骨的物理化学特性.
- 探索最先进的内关节软骨向DDS用于OA治疗.
- 了解OA治疗DDS的最新进展.
主要方法:
- 关节软骨的物理化学性质的审查 (多孔性,负电荷).
- 对DDSs的正电荷生物材料 (多氨基酸,蛋白质,聚合物,脂质) 的分析.
- 评估被动 (与GAG的静电相互作用) 和活性 (抗体/向) 的软骨透策略.
主要成果:
- 带正电荷的DDS利用软骨的负电荷来增强透和保留.
- 阴离子纳米载体与ECM糖氨酸糖之间发生静电相互作用.
- 通过用原II/冠状细胞亲和分子进行表面装饰来进行主动准显示出有希望的结果.
结论:
- 了解软骨的生物物理化学特性是设计有效的DDS的关键.
- 带正电荷的DDS为改善OA的关节内药物输送提供了可行的策略.
- 针对软骨的DDS的进展对于开发新型OA疗法至关重要.
相关概念视频
Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...


